Gilead Sciences (GILD) to Resume Trading at 4:25PM ET Following Strong Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends up on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
About 9,000 Hep C patients have been cured with Sovaldi to date - Gilead (GILD)
July 23, 2014 4:48 PM EDTGilead Sciences (NASDAQ: GILD) said about 9,000 Hep C patients have been cured with Sovaldi to date
... MoreGilead Sciences, Inc. (GILD) Tops Q2 EPS by 63c; Boosts FY14 Revenue Outlook
July 23, 2014 4:07 PM EDTGilead Sciences, Inc. (NASDAQ: GILD) reported Q2 EPS of $2.36, $0.63 better than the analyst estimate of $1.73. Revenue for the quarter came in at $6.53 billion versus the consensus estimate of $5.68 billion.
During the second quarter, Gilead continued to make significant progress led by strong Sovaldi sales. Since Decembers launch, Sovaldi has been prescribed for more than 80,000 patients in the U.S. and Europe, underscoring the medical communitys recognition of the benefits of this product, said John C. Martin, PhD, Gileads Chairman and Chief Executive Officer. We look forward to making Sovaldi available in additional... More
